

# NEWS RELEASE



January 10, 2025

## **NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy notice regarding publication of the results of an investigator-initiated clinical trial (First in human trial)**

**Kyoto, Japan, January 10, 2025** - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) has published the results of an investigator-initiated clinical trial (First in human trial) of NS-089/NCNP-02, which is being developed by Nippon Shinyaku for the treatment of Duchenne muscular dystrophy (DMD), in the journal *Cell Reports Medicine*. Please check the press release from NCNP for summary of the paper. <https://www.ncnp.go.jp/topics/detail.php?@uid=GHiBUYrxzfWih41S>

Additionally, the paper is available for free viewing.

[https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791\(24\)00672-4](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00672-4)

NS-089/NCNP-02 is a nucleic acid drug co-discovered by Nippon Shinyaku and NCNP, and is expected to be a therapeutic drug for DMD patients with dystrophin gene mutations amenable to exon 44 skipping.

A global Phase II study of NS-089/NCNP-02 is being conducted by Nippon Shinyaku and NS Pharma, Inc. (Headquarters: New Jersey, USA; President: Yukiteru Sugiyama).

Nippon Shinyaku has been working actively with a sense of mission to develop agents for the treatment of intractable and rare diseases, with a view to launching products for DMD patients as soon as possible.

### **Contact**

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.

[e\\_mail\\_kouhou@po.nippon-shinyaku.co.jp](mailto:e_mail_kouhou@po.nippon-shinyaku.co.jp)